GlassScriptPhysician profile
Benjamin L Leggio
NPI 1851370332
$2,340.70
in general payments reported to CMS, 2019-2025
24 companies · $655 in 2025
The $655 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $142 · 2021: $348 · 2022: $367 · 2023: $105 · 2024: $428 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $325.39 | 2025 | Omnipod, Omnipod |
| Lilly USA, LLC | $307.90 | 2019-2024 | Jardiance |
| Amgen INC. | $288.29 | 2023-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $226.76 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $205.09 | 2021-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $173.04 | 2020-2024 | Rybelsus |
| Astellas Pharma US INC | $144.97 | 2024 | Veozah |
| Pfizer INC. | $112.78 | 2019-2025 | |
| Mylan Specialty L.P. | $87.42 | 2022-2024 | Yupelri |
| Abbvie INC. | $64.83 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $56.69 | 2022 | |
| Sunovion Pharmaceuticals INC. | $49.17 | 2020 | |
| Axsome Therapeutics, INC. | $47.60 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $37.73 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $35.55 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $31.69 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $30.90 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $22.40 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.69 | 2024 | Rexulti |
| Dexcom, INC. | $17.18 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.24 | 2024 | Jardiance |
| Allergan, INC. | $14.70 | 2020 | |
| Daiichi Sankyo INC. | $12.46 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Leggio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.